Given the evolution of relying on CSF amyloid-β and tau biomarkers in enhancing diagnostic accuracy of the early stages of Alzheimer’s disease, we aimed to conduct this study in biomarker-positive Alzheimer’s disease individuals. The gene discussed is MAPT; the disease is early-onset autosomal dominant Alzheimer disease.